Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

Keyword: Clinical Efficacy

Publisher: PRNewswire

Published: Jul 22, 2026

Cardiovascular disease remains the leading cause of mortality worldwide, with elevated LDL cholesterol levels serving as a major modifiable risk factor. While currently approved PCSK9 (proprotein con… [+7014 chars]

Read Full Story ↗